Indication: Juvenile Idiopathic Arthritis (JIA)

A Randomized, Open Label, Multi-Center, Phase 3 Efficacy Study of Sub-Q Abatacept (Orencia) in Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (LIMIT-JIA)

Sub-indication: Juvenile Idiopathic Arthritis (JIA)

Drug Study

Principal Investigator: Kenneth Schikler, M.D.
Norton Children's Rheumatology, affiliated with the UofL School of Medicine

Sponsor: PCORI

Search our entire site.